Hot Research PM

Geron Gets a Lift From Good Data

MLV & Co. raised the price target on the biotech.

December 10, 2013

Geron (GERN: Nasdaq) By MLV & Co. ($5.52, Dec. 10, 2013)

Following Monday's positive American Society of Hematology Abstracts data for Imetelstat in myelofibrosis, we now raise our price target of Buy-rated Geron to $9 from $8 on increased confidence in Imetelstat's prospects.

Despite skepticism that is likely to persist given circumstances of the data presented, the big picture is that Geron (ticker: GERN) possesses...